Finn's Take· TL;DRJohn Thomas Howard, treasurer and a director of Canadian prescription drug company CanaRx, faces smuggling and conspiracy charges after his arrest on November 8. The case has sent shockwaves through the healthcare industry, raising urgent questions about the booming market for cheaper foreign drugs — and just how far some companies will go to profit from America's sky-high prescription prices.
Howard was taken into custody on counts of smuggling and conspiracy, plus charges tied to misbranded drugs and unlawful importation. No plea has yet been submitted. His brother, Bob Howard, is CanaRx's president and a director, and he is sought as part of the federal probe and remains at large.
Federal prosecutors allege a multi-year scheme involving the illegal importation of misbranded prescription medications from foreign jurisdictions into the U.S. The criminal complaint covers activities from February 22, 2017, through April 15, 2026, as regulators increase enforcement against offshore drug procurement.
FDA special agent Dustin Dobbs wrote in an affidavit that "there is probable cause to believe that CanaRx illegally imported or caused the illegal importation of prescription drugs into the United States." The affidavit does not specify which medications the agency believes were illegally imported. However, the scope is broad: Gilead Sciences has initiated a civil lawsuit against CanaRx and other entities, alleging the illegal importation of Biktarvy, a medication used for HIV treatment.
The company has been under FDA scrutiny for several years. In 2019, the FDA sent a warning letter to the company, saying it was operating "in a manner that substitutes the FDA-approved drugs prescribed by the U.S. healthcare provider with unapproved drugs." In response to that warning, CanaRx's general counsel argued the company was not misleading patients, but agreed for the company to stop importing drugs that need to be administered by a doctor.
CanaRx had been featured in a prior investigation that revealed how the company and others known as alternative funding programs, or AFPs, are becoming more pervasive around the U.S. as drug costs skyrocket. The investigation found these companies have penetrated the country's healthcare system by offering high-cost specialty drugs at more affordable prices through private and public employers. In some cases, employers are requiring their staff to use an AFP.
Federal authorities have noted that buying medicines abroad and shipping them directly to patients is illegal and raises safety concerns. That hasn't stopped demand from growing. For millions of Americans crushed by prescription costs, the appeal of cheaper foreign drugs is obvious — but the CanaRx case illustrates the risks lurking beneath the surface when those supply chains operate outside the law.
The company's general counsel, Joseph Morris, told reporters in a statement: "The Howards deny all the charges against them, will defend vigorously, and expect to be vindicated in court." The company has said it sources its medications from Canada, the United Kingdom, Australia, and New Zealand.
The case arrives at a politically charged moment. Drug pricing reform has dominated policy debates for years, and the CanaRx arrests underscore just how much legal gray area — and outright lawbreaking — has flourished in that vacuum. While Americans struggle with healthcare costs that often exceed those in other developed nations, federal regulations restrict drug importation to maintain safety standards and supply chain integrity. As healthcare costs remain a persistent concern for American families and businesses, authorities face the challenge of balancing affordability with patient safety and regulatory compliance under existing federal law. With Bob Howard still at large and federal prosecutors pressing forward, this case is far from over.